Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Oct 1, 2013)
  • 8-K (Sep 12, 2013)
  • 8-K (Aug 20, 2013)
  • 8-K (Aug 19, 2013)
  • 8-K (Jun 24, 2013)
  • 8-K (May 1, 2013)

 
Other

VANGUARD HEALTH SYSTEMS 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Graphic
  3. Graphic
VANGUARD HEALTH SYSTEMS, INC.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934



Date of Report (Date of earliest event reported)   November 20, 2012 (November 15, 2012)   



VANGUARD HEALTH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

          DELAWARE          

 

               001-35204                 

 

          62-1698183          

 

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 


20 Burton Hills Boulevard, Suite 100, Nashville, Tennessee

 


     37215     

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code        (615) 665-6000     

          Not applicable          
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

______________________________


Item 5.07        Submission of Matters to a Vote of Security Holders.

(a)        Vanguard Health Systems, Inc. (the “Company”) held its annual meeting of stockholders on November 15, 2012.

(b)        At the annual meeting, the stockholders (1) elected all of the Company’s Board of Director’s nominees for director, (2) ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2013 and (3) approved an advisory resolution on the compensation paid to the Company’s named executive officers.

The final results of voting on each of the matters submitted to a vote are as follows:

1.         Election of directors

FOR

 

WITHHELD

 

ABSTAIN

 

BROKER
NON-VOTES





Michael A. Dal Bello

53,297,347

11,657,191

8,528,542

M. Fazle Husain

53,877,982

11,076,556

8,528,542

     

2.         Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2013

FOR

 

AGAINST

 

ABSTAIN

 

BROKER
NON-VOTES





72,819,249

613,831

50,000

N/A

     

3.         Advisory vote on the compensation paid to the Company’s named executive officers

FOR

 

AGAINST

 

ABSTAIN

 

BROKER
NON-VOTES





64,490,013

309,015

155,510

8,528,542


SIGNATURES

            Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                                                        VANGUARD HEALTH SYSTEMS, INC.
                                                                                                (Registrant)

DATE:   November 20, 2012                           By: /s/ James H. Spalding                                    
                                                                               James H. Spalding
                                                                               Executive Vice President, General Counsel and Secretary

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki